Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended July 31, 1996
Business Overview: The Company develops, manufactures, and markets healthcare products (contact lenses, surgical instruments) and provides healthcare services through psychiatric facilities (Hospital Group of America, Inc. or HGA).
Key Financial Metrics
| Metric (in thousands) | 9 Months Ended July 31, 1996 | 9 Months Ended July 31, 1995 |
|---|---|---|
| Net Operating Revenue | $77,895 | $72,253 |
| Income from Operations | $11,248 | $5,422 |
| Net Income | $8,130 | $3,700 |
| Earnings Per Share (EPS) | $0.69 | $0.32 |
| Cash and Cash Equivalents (End of Period) | $3,143 | $8,786 |
| Net Cash Used by Operating Activities | $(2,094) | $(1,651) |
| Total Debt (Current + Long-term) | $49,775 | $45,778 |
| Stockholders' Equity | $6,510 | $(1,749) |
Note: Debt figures include current installments of long-term debt and borrowings under lines of credit.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenue increased 7.8% year-over-year for the nine-month period. Product sales rose 17% ($47.3M vs $40.3M), driven by CooperVision (CVI) and CooperSurgical (CSI). Service revenue remained relatively flat (-1.9%) due to managed care pressures.
- Profitability Surge: Income from operations more than doubled, increasing 107% to $11.2M. Net income rose 120% to $8.1M.
- Margin Expansion: Gross margin on products improved to 70% (from 68%) due to production efficiencies and a favorable mix of high-margin toric contact lenses.
- Acquisition Impact: The April 1996 acquisition of Unimar, Inc. contributed $1.9M in sales and added $7.5M in goodwill. Initial margins on Unimar products were lower than the company average.
- Equity Turnaround: Stockholders' equity improved by $8.3M, moving from a deficit of $1.7M to a positive $6.5M.
- Cash Flow: Operating cash flow remained negative for the nine-month period ($2.1M used), primarily due to dispute settlements ($4.9M), bonus payments ($2.0M), and increased working capital investments ($3.3M). However, the quarter ended July 31 showed positive operating cash flow of $5.3M.
Guidance, Outlook, and Risks
- Fiscal 1996 Outlook: Management anticipates full-year EPS between $1.30 and $1.35. This includes an estimated deferred tax benefit of $0.30 per share. Revenue is expected to achieve double-digit growth.
- Segment Expectations:
- CooperVision: Expected mid-teens sales growth driven by toric lens market share gains.
- CooperSurgical: Income from operations expected to reach 10% of sales for the full year, aided by the Unimar acquisition.
- HGA: Expected to outperform 1995 results due to the turnaround at Hampton Hospital and new outpatient clinics.
- Debt Restructuring: The Company is finalizing an amendment to its $11M HGA term loan, expecting a 2% interest rate reduction effective in fiscal 1997. A 1% rate reduction was also secured on the CVI line of credit.
- Risks and Contingencies:
- Managed care trends continue to pressure service revenue (lower daily rates, shorter stays).
- Unusual items include a $223k credit from the settlement of disputes with Progressions Health Systems and a $615k tax benefit from the reversal of state tax accruals.
- Future acquisitions may require additional capital raising.
Investor Verification Checklist
- Deferred Tax Benefit: Verify the realization of the anticipated $0.30 per share deferred tax benefit included in the EPS guidance.
- Unimar Integration: Monitor whether Unimar product margins improve as projected following the initial low-margin period.
- Debt Amendment: Confirm the execution of the HGA loan amendment and the resulting interest rate reduction.
- Working Capital: Track the trend in receivables, particularly at HGA, where a shift to slower-paying state agencies has increased days sales outstanding.
- Operating Cash Flow: Validate the projection that operating cash flows will remain positive for the remainder of fiscal 1996 to cover debt repayments.